Combining Molecularly Targeted Agents: Is More Always Better?
The concurrent targeting of critical nodes along key signaling pathways with molecularly targeted agents is a rational antitumor strategy, which has had varying degrees of success. Combinatorial challenges include overcoming synergistic toxicities and establishing whether combinations are truly active, to make "go, no-go" decisions to proceed to later phase trials.Clin Cancer Res; 23(5); 1123-5. ©2016 AACRSee related article by Calvo et al., p. 1177.
Royal Marsden Hospital, London, United Kingdom.
Raghav
R
Sundar
Royal Marsden Hospital, London, United Kingdom.|The Institute of Cancer Research, London, United Kingdom.
Nicola
N
Valeri
Royal Marsden Hospital, London, United Kingdom.|The Institute of Cancer Research, London, United Kingdom.
Kevin J
KJ
Harrington
Royal Marsden Hospital, London, United Kingdom. timothy.yap@icr.ac.uk.|The Institute of Cancer Research, London, United Kingdom.
Timothy A
TA
Yap
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy*; D015398:Signal Transduction / Q000187:drug effects